3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012

Virology

Volumn 490, Issue , 2016, Pages 49-58

  Johnson, Reed F ^a   Bagci, Ulas ^b,f   Keith, Lauren ^a   Tang, Xianchun ^c   Mollura, Daniel J ^b   Zeitlin, Larry ^d   Qin, Jing ^a   Huzella, Louis ^a   Bartos, Christopher J ^a   Bohorova, Natasha ^d   Bohorov, Ognian ^d   Goodman, Charles ^d   Kim, Do H ^d   Paulty, Michael H ^d   Velasco, Jesus ^d   Whaley, Kevin J ^d   Johnson, Joshua C ^a   Pettitt, James ^a   Ork, Britini L ^a   Solomon, Jeffrey ^g   Oberlander, Nicholas ^a   Zhu, Quan ^c   Sun, Jiusong ^c   Holbrook, Michael R ^a   Olinger, Gene G ^a   Baric, Ralph S ^e   Hensley, Lisa E ^a   Jahrling, Peter B ^a   Marasco, Wayne A ^c   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Mapp Biopharmaceutical Inc   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CENTRAL FLORIDA   (United States)

^g FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

Animal model, MERS; Antibody therapy; Human monoclonal antibody therapy; MERS CoV; Respiratory syndrome

Indexed keywords

ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3B11 N; MONOCLONAL ANTIBODY E410 N; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONAVIRUS INFECTION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INOCULATION; INTRATRACHEAL INOCULATION; LUNG INFECTION; LUNG LAVAGE; LUNG VOLUME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS JORDAN N3 2012; NONHUMAN; OXYGEN SATURATION; PILOT STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RHESUS MONKEY; TOTAL LUNG CAPACITY; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; CORONAVIRUS INFECTIONS; DISEASE MODEL; HUMAN; LUNG; MALE; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; HUMANS; LUNG; MACACA MULATTA; MALE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS;

EID: 84961381392     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2016.01.004     Document Type: Article

References (36)

1. Adney D.R., van Doremalen N., Brown V.R., Bushmaker T., Scott D., de Wit E., Bowen R.A., Munster V.J. Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg. Infect. Dis. 2014, 20:1999-2005.
2. Agrawal A.S., Garron T., Tao X., Peng B.H., Wakamiya M., Chan T.S., Couch R.B., Tseng C.T. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J. Virol. 2015, 89:3659-3670.
3. Bossart K.N., Zhu Z., Middleton D., Klippel J., Crameri G., Bingham J., McEachern J.A., Green D., Hancock T.J., Chan Y.P., Hickey A.C., Dimitrov D.S., Wang L.F., Broder C.C. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog. 2009, 5:e1000642.
4. Channappanavar R., Fett C., Zhao J., Meyerholz D.K., Perlman S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J. Virol. 2014, 88:11034-11044.
5. Channappanavar R., Zhao J., Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol. Res. 2014, 59:118-128.
6. Corman VM1, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, van Boheemen S, Gopal R, Ballhause M, Bestebroer TM, Muth D, Müller MA, Drexler JF, Zambon M, Osterhaus AD, Fouchier RM, Drosten C. 2012. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction., Euro Surveillance 17(39).
7. de Groot R.J., Baker S.C., Baric R.S., Brown C.S., Drosten C., Enjuanes L., Fouchier R.A., Galiano M., Gorbalenya A.E., Memish Z.A., Perlman S., Poon L.L., Snijder E.J., Stephens G.M., Woo P.C., Zaki A.M., Zambon M., Ziebuhr J. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J. Virol. 2013, 87:7790-7792.
8. de Wit E., Rasmussen A.L., Falzarano D., Bushmaker T., Feldmann F., Brining D.L., Fischer E.R., Martellaro C., Okumura A., Chang J., Scott D., Benecke A.G., Katze M.G., Feldmann H., Munster V.J. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc. Natl. Acad. Sci. USA 2013, 110:16598-16603.
9. Falzarano D., de Wit E., Feldmann F., Rasmussen A.L., Okumura A., Peng X., Thomas M.J., van Doremalen N., Haddock E., Nagy L., LaCasse R., Liu T., Zhu J., McLellan J.S., Scott D.P., Katze M.G., Feldmann H., Munster V.J. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 2014, 10:e1004250.
10. Giritch A., Marillonnet S., Engler C., van Eldik G., Botterman J., Klimyuk V., Gleba Y. Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc. Natl. Acad. Sci. USA 2006, 103:14701-14706.
11. Gossner C., Danielson N., Gervelmeyer A., Berthe F., Faye B., Kaasik Aaslav K., Adlhoch C., Zeller H., Penttinen P., Coulombier D. Human-dromedary camel interactions and the risk of acquiring zoonotic Middle East Respiratory syndrome coronavirus infection. Zoonoses Public Health 2014.
12. Haley P.J., Muggenburg B.A., Rebar A.H., Shopp G.M., Bice D.E. Bronchoalveolar lavage cytology in cynomolgus monkeys and identification of cytologic alterations following sequential saline lavage. Vet. Pathol. 1989, 26:265-273.
13. Jiang L., Wang N., Zuo T., Shi X., Poon K.M., Wu Y., Gao F., Li D., Wang R., Guo J., Fu L., Yuen K.Y., Zheng B.J., Wang X., Zhang L. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci. Transl. Med. 2014, 6:234ra259.
14. Johnson R.F., Via L.E., Kumar M.R., Cornish J.P., Yellayi S., Huzella L., Postnikova E., Oberlander N., Bartos C., Ork B.L., Mazur S., Allan C., Holbrook M.R., Solomon J., Johnson J.C., Pickel J., Hensley L.E., Jahrling P.B. Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease. Virology 2015, 485:422-430.
15. Khalafalla A.I., Lu X., Al-Mubarak A.I., Dalab A.H., Al-Busadah K.A., Erdman D.D. MERS-CoV in Upper respiratory tract and lungs of dromedary camels, Saudi Arabia, 2013-2014. Emerg. Infect. Dis. 2015, 21:1153-1158.
16. Laird N.M., Ware J.H. Random-effects models for longitudinal data. Biometrics 1982, 38:963-974.
17. Mansoor A., Bagci U., Xu Z., Foster B., Olivier K.N., Elinoff J.M., Suffredini A.F., Udupa J.K., Mollura D.J. A generic approach to pathological lung segmentation. IEEE Trans. Med. Imaging 2014, 33:2293-2310.
18. Marasco W.A., Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat. Biotechnol. 2007, 25:1421-1434.
19. Munster V.J., de Wit E., Feldmann H. Pneumonia from human coronavirus in a macaque model. N Engl. J. Med. 2013, 368:1560-1562.
20. Pascal K.E., Coleman C.M., Mujica A.O., Kamat V., Badithe A., Fairhurst J., Hunt C., Strein J., Berrebi A., Sisk J.M., Matthews K.L., Babb R., Chen G., Lai K.M., Huang T.T., Olson W., Yancopoulos G.D., Stahl N., Frieman M.B., Kyratsous C.A. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc. Natl. Acad. Sci. USA 2015, 112:8738-8743.
21. Pebody R.G., Chand M.A., Thomas H.L., Green H.K., Boddington N.L., Carvalho C., Brown C.S., Anderson S.R., Rooney C., Crawley-Boevey E., Irwin D.J., Aarons E., Tong C., Newsholme W., Price N., Langrish C., Tucker D., Zhao H., Phin N., Crofts J., Bermingham A., Gilgunn-Jones E., Brown K.E., Evans B., Catchpole M., Watson J.M. The United Kingdom public health response to an imported laboratory confirmed case of a novel coronavirus in September 2012. Euro Surveill.: Bull. Eur. sur Les Mal. Transm. Eur. Commun. Dis. Bull. 2012, 17:8-11.
22. Qiu X., Kobinger G.P. Antibody therapy for Ebola: is the tide turning around?. Hum. Vaccines Immunother. 2014, 10:964-967.
23. Raj V.S., Mou H., Smits S.L., Dekkers D.H., Muller M.A., Dijkman R., Muth D., Demmers J.A., Zaki A., Fouchier R.A., Thiel V., Drosten C., Rottier P.J., Osterhaus A.D., Bosch B.J., Haagmans B.L. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013, 495:251-254.
24. Shadman K.A., Wald E.R. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert. Opin. Biol. Ther. 2011, 11:1455-1467.
25. Strasser R., Stadlmann J., Schahs M., Stiegler G., Quendler H., Mach L., Glossl J., Weterings K., Pabst M., Steinkellner H. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol. J. 2008, 6:392-402.
26. Tang X.C., Agnihothram S.S., Jiao Y., Stanhope J., Graham R.L., Peterson E.C., Avnir Y., Tallarico A.S., Sheehan J., Zhu Q., Baric R.S., Marasco W.A. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc. Natl. Acad. Sci. USA 2014, 111:E2018-E2026.
27. Von Essen S.G., Robbins R.A., Spurzem J.R., Thompson A.B., McGranaghan S.S., Rennard S.I. Bronchoscopy with bronchoalveolar lavage causes neutrophil recruitment to the lower respiratory tract. Am. Rev. Respir. Dis. 1991, 144:848-854.
28. Wang L., Shi W., Joyce M.G., Modjarrad K., Zhang Y., Leung K., Lees C.R., Zhou T., Yassine H.M., Kanekiyo M., Yang Z.Y., Chen X., Becker M.M., Freeman M., Vogel L., Johnson J.C., Olinger G., Todd J.P., Bagci U., Solomon J., Mollura D.J., Hensley L., Jahrling P., Denison M.R., Rao S.S., Subbarao K., Kwong P.D., Mascola J.R., Kong W.P., Graham B.S. Evaluation of candidate vaccine approaches for MERS-CoV. Nat. Commun. 2015, 6:7712.
29. Xu Z., Bagci U., Foster B., Mansoor A., Mollura D.J., 2013. Spatially constrained random walk approach for accurate estimation of airway wall surfaces. Medical image computing and computer-assisted intervention: MICCAI International Conference on Medical Image Computing and Computer-Assisted Intervention, 16. p. 559-66.
30. Yao Y., Bao L., Deng W., Xu L., Li F., Lv Q., Yu P., Chen T., Xu Y., Zhu H., Yuan J., Gu S., Wei Q., Chen H., Yuen K.Y., Qin C. An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus. J. Infect. Dis. 2014, 209:236-242.
31. Ying T., Li H., Lu L., Dimitrov D.S., Jiang S. Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. Microbes Infect. 2015, 17:142-148. institut Pasteur.
32. Yusof M.F., Eltahir Y.M., Serhan W.S., Hashem F.M., Elsayed E.A., Marzoug B.A., Abdelazim A.S., Bensalah O.K., Al Muhairi S.S. Prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Abu Dhabi Emirate, United Arab Emirates. Virus Genes 2015, 50:509-513.
33. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl. J. Med. 2012, 367:1814-1820.
34. Zeitlin L., Bohorov O., Bohorova N., Hiatt A., Kim do H., Pauly M.H., Velasco J., Whaley K.J., Barnard D.L., Bates J.T., Crowe J.E., Piedra P.A., Gilbert B.E. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. mAbs 2013, 5:263-269.
35. Zhao J., Li K., Wohlford-Lenane C., Agnihothram S.S., Fett C., Zhao J., Gale M.J., Baric R.S., Enjuanes L., Gallagher T., McCray P.B., Perlman S. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl. Acad. Sci. USA 2014, 111:4970-4975.
36. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001, 75:10892-10905.